Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359038 | 1.00 | NOD1 (0.59) | NOD1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL12804895 | 1.00 | NOD1 (0.59) | NOD1PTGS1GSTK1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL9548427 | 0.99 | NOD1 (0.58) | NOD1PTGS1GSTK1KMT2APOLB | |
| Cysteamine SCHEMBL20768360 | 0.95 | NOD1 (0.55) | NOD1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL1217963 | 0.91 | NOD1 (0.55) | NOD1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL1217960 | 0.91 | NOD1 (0.55) | NOD1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL4577767 | 0.88 | PTGS1 (0.62) | NOD1PTGS1GSTK1GLO1FOLH1 | |
| SCHEMBL3664823 | 0.87 | NOD1 (0.60) | NOD1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL3664829 | 0.87 | NOD1 (0.60) | NOD1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL10489000 | 0.84 | NOD1 (0.73) | NOD1PTGS1GSTK1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 892 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118552198-B | Unified management method for payment channels | 无锡锡商银行股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-112651146-B | Street lamp or signal lamp post structure calculation and check method | 扬州市法马智能设备有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-114719764-A | Bubble liquid film thickness testing device based on laser interference system | 交通运输部公路科学研究所 | 2022-07-08 | — | — | CN | claimed |
| US-20200323883-A1 | METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | ENTERIN, INC. (US) | 2020-10-15 | — | — | US | claimed |
| US-10478444-B2 | Methods and compositions for treating and preventing viral infections | ENTERIN, INC. (US) | 2019-11-19 | — | — | US | claimed |
| US-20180133230-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONS | ENTERIN LABORATORIES, INC. (US) | 2018-05-17 | — | — | US | claimed |
| US-20140328792-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONS | ENTERIN, INC. | 2014-11-06 | — | — | US | claimed |
| WO-2011066260-A2 | FORMULATIONS COMPRISING AMINOSTEROLS | ZASLOFF MICHAEL (US) | 2011-06-03 | — | — | WO | claimed |
| US-20110123624-A1 | FORMULATIONS COMPRISING AMINOSTEROLS | ENTERIN, INC. | 2011-05-26 | — | — | US | claimed |
| WO-2011056650-A2 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONS | ZASLOFF MICHAEL (US) | 2011-05-12 | — | — | WO | claimed |
| US-20110097303-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONS | ENTERIN, INC. | 2011-04-28 | — | — | US | claimed |
| EP-0276317-B1 | GAMMA-L-GLUTAMYL-L-CYSTEINE ETHYL ESTER AND DRUG CONTAINING IT AS EFFECTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1993-03-17 | — | — | EP | claimed |
| US-4927808-A | GLUTATHIONE LEVELS IN TISSUES | TEIJIN LIMITED (JP) | 1990-05-22 | — | — | US | claimed |
| CN-116769738-B | Glutamyl cysteine synthetase mutant and application thereof in glutathione synthesis | 江苏集萃工业生物技术研究所有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12569456-B2 | Methods for the treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-120548360-A | Composition for inhibiting tyrosinase activity | 三菱商事生命科学株式会社 | 2025-08-26 | — | — | CN | disclosed |
| US-4927808-A | GLUTATHIONE LEVELS IN TISSUES | TEIJIN LIMITED (JP) | 1990-05-22 | — | — | US | disclosed |
| EP-0276317-A4 | GAMMA-L-GLUTAMYL-L-CYSTEINE ETHYL ESTER AND DRUG CONTAINING IT AS EFFECTIVE INGREDIENT. | TEIJIN LTD (JP) | 1989-09-19 | — | — | EP | disclosed |
| EP-0276317-A1 | GAMMA-L-GLUTAMYL-L-CYSTEINE ETHYL ESTER AND DRUG CONTAINING IT AS EFFECTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1988-08-03 | — | — | EP | disclosed |
| WO-1988000182-A1 | gamma-L-GLUTAMYL-L-CYSTEINE ETHYL ESTER AND DRUG CONTAINING IT AS EFFECTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1988-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328792-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONS | STING1, IFNG, TSLP | NOD1 92/4885PTGS1 215/4885GSTK1 784/4885 |
| US-10478444-B2 | Methods and compositions for treating and preventing viral infections | STING1, IFNG, TSLP | NOD1 92/4885PTGS1 215/4885GSTK1 784/4885 |
| US-12569456-B2 | Methods for the treatment of cysteamine sensitive disorders | SLC7A11, CTH, SLC19A1 | NOD1 3764/4885PTGS1 365/4885GSTK1 19/4885 |
| US-20110123624-A1 | FORMULATIONS COMPRISING AMINOSTEROLS | HSD3B1, CYP17A1, HSD3B2 | NOD1 4814/4885PTGS1 600/4885GSTK1 1029/4885 |
| US-20180133230-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONS | STING1, IFNG, TSLP | NOD1 92/4885PTGS1 215/4885GSTK1 784/4885 |
| US-20110097303-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONS | STING1, IFNG, TSLP | NOD1 92/4885PTGS1 215/4885GSTK1 784/4885 |
| US-20200323883-A1 | METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | STING1, TSLP, MAVS | NOD1 113/4885PTGS1 233/4885GSTK1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.